Alopecia Areata (Investigational Adjunct)
Investigational adjunct for stable patchy alopecia areata; case reports only; intralesional corticosteroids and JAK inhibitors (baricitinib, ritlecitinib) remain primary.
Краткая информация для пациента
- Есть ли FDA-допуск для этого показания?
- Not FDA-cleared for alopecia areata. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for alopecia areata is investigational.
- Какие доказательства существуют?
- Tier C (investigational). Only anecdotal case reports; no randomized trials. Evidence-based therapy per AAD includes intralesional triamcinolone for limited patches (first line), topical immunotherapy with diphenylcyclopropenone (DPCP) for extensive disease, oral JAK inhibitors baricitinib (FDA-approved 2022) and ritlecitinib (FDA-approved 2023) for severe disease, topical and oral minoxidil as adjuncts, and topical / systemic corticosteroids. JAK inhibitors directly target the interferon-gamma / CD8+ T-cell pathway driving the disease.
- Основные риски
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the scalp for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Triggering further hair loss at or near the bite sites in active disease
- Permanent visible scars at bite sites
- Delay or replacement of intralesional steroid or JAK inhibitor therapy with potential disease progression
- Кому не следует это рассматривать
- Patients with alopecia totalis or universalis (consider JAK inhibitors)
- Patients with active progressive AA in the last 3 months
- Patients on JAK inhibitor therapy (drug interaction unknown, theoretical bleeding risk)
- Patients with scalp psoriasis or seborrheic dermatitis at proposed sites
- Patients with diffuse hair loss not confirmed to be AA (needs workup)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- О чём спросить врача
- Has my diagnosis been confirmed (clinical exam, dermoscopy, or biopsy)?
- What is my SALT (Severity of Alopecia Tool) score, and what is the disease pattern?
- Have I tried intralesional triamcinolone for limited patches?
- Am I a candidate for a JAK inhibitor (baricitinib or ritlecitinib) for severe disease?
- What is the natural history of my AA, and has there been spontaneous regrowth?
- What is the realistic effect size with leech therapy versus proven options?
- What is the practitioner's experience and Aeromonas-prevention plan?
- Когда срочно обратиться за медицинской помощью
- Rapidly progressive hair loss across multiple body sites (suggests systemic autoimmune activity)
- Total or universal alopecia (consider urgent dermatology referral for JAK inhibitor)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Eye redness, pain, or vision change (associated alopecia areata can have ocular involvement)
- Hives, throat tightness, or breathing difficulty
Что это НЕ означает
- This is not FDA-cleared for alopecia areata.
- Anecdotal reports do NOT establish efficacy versus intralesional triamcinolone or oral JAK inhibitors.
- Mechanism rationale (local immune modulation, follicle stimulation) does NOT address the autoimmune CD8+ T-cell pathway.
- Spontaneous regrowth is common in AA — uncontrolled reports cannot distinguish therapy from natural history.
- Leech therapy is not a substitute for proven intralesional steroid or JAK inhibitor therapy.
Перекрёстные ссылки безопасности
Clinical Profile
- Category
- dermatological
- ICD-10
- L63.0, L63.1, L63.2, L63.9
- Safety tier
- medium
Evidence Summary
Alopecia areata management per the AAD includes intralesional triamcinolone for limited patches, topical immunotherapy (DPCP) for extensive disease, oral baricitinib and ritlecitinib (FDA-approved 2022 and 2023) for severe disease, and topical minoxidil as an adjunct. No controlled clinical trial of leech therapy for alopecia areata has been published; its use is investigational and mechanistic only. The autoimmune pathophysiology (interferon-gamma-driven CD8+ T-cell attack on the hair follicle bulb) is unlikely to be addressed by peripheral leech application, whereas JAK inhibitors directly target this pathway. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Sotnikov OS et al. (2010)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Alopecia totalis or universalis (consider JAK inhibitor)
- Active progressive AA (consider systemic therapy first)
- Concurrent JAK inhibitor (drug interaction unknown)
- Scalp psoriasis or seborrheic dermatitis at proposed site
- Diffuse alopecia (not AA — workup needed)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.